title: Efficacy of micafungin in pediatric immunocompromised patients with invasive fungal infection.
abstract: BACKGROUND
  Micafungin, an antifungal echinocandin, has been indicated for pediatric patients with invasive fungal infection (IFI) in Japan and Europe. Its efficacy in immunocompromised pediatric patients with IFI, however, has not been fully investigated.
  
  
  METHODS
  The safety and efficacy of micafungin as an antifungal therapy were analyzed in nine consecutive severe immunocompromised patients with IFI.
  
  
  RESULTS
  Three patients with proven or probable Candida infections had complete response to micafungin therapy. Of the other six patients with proven, probable or possible Aspergillus infection, four had complete response and one had partial response to micafungin treatment. No severe adverse events were observed.
  
  
  CONCLUSIONS
  In this small series, micafungin was effective for IFI caused by both Candida and Aspergillus species and no severe adverse events were observed in these immunocompromised patients.
authors.affiliation: Department of Developmental Medicine, Osaka University Graduate School of Medicine, Suita, Japan.
authors.forename: Yoshiko
authors.initials: Y
authors.lastname: Hashii
authors.affiliation: Department of Pediatrics, National Hospital Organization Osaka National Hospital, Osaka, Japan.
authors.forename: Shigenori
authors.initials: S
authors.lastname: Kusuki
authors.affiliation: Department of Pediatrics, Ikeda City Hospital, Ikeda, Japan.
authors.forename: Sachiko
authors.initials: S
authors.lastname: Takizawa
authors.affiliation: Department of Pediatrics, Osaka City University Graduate School of Medicine, Osaka, Japan.
authors.forename: Sadao
authors.initials: S
authors.lastname: Tokimasa
authors.affiliation: Department of Pediatrics, Higashitoyonakawatanabe Hospital, Osaka, Japan.
authors.forename: Hideaki
authors.initials: H
authors.lastname: Ohta
authors.affiliation: Department of Pediatric Hematology/Oncology, Osaka City General Hospital, Osaka, Japan.
authors.forename: Junichi
authors.initials: J
authors.lastname: Hara
authors.affiliation: Department of Developmental Medicine, Osaka University Graduate School of Medicine, Suita, Japan.
authors.forename: Keiichi
authors.initials: K
authors.lastname: Ozono
mesh_terms: D000293:Adolescent; D000935:Antifungal Agents / Q000627:therapeutic use*; D001228:Aspergillosis / Q000188:drug therapy*; D002177:Candidiasis / Q000188:drug therapy*; D002648:Child; D002675:Child, Preschool; D015331:Cohort Studies; D054714:Echinocandins / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D016867:Immunocompromised Host; D007223:Infant; D055666:Lipopeptides / Q000627:therapeutic use*; D008297:Male; D000077551:Micafungin; D016896:Treatment Outcome
chemical_list: D000935:Antifungal Agents; D054714:Echinocandins; D055666:Lipopeptides; D000077551:Micafungin
keywords: immunocompromised host; invasive fungal infection; micafungin; pediatric patient